Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Industry
Miscellaneous Chemical Products
Location
771 Jamacha Road #512, El Cajon, CA
State of incorporation
DE
Fiscal year end
July 31
Former names
PURE BIOSCIENCE (to 3/17/2011), INNOVATIVE MEDICAL SERVICES (to 9/2/2003)
Latest financial report
10-Q - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 99.1 % -58.4%
Quick Ratio 8.72 % -48.4%
Debt-to-equity -125 %
Return On Equity 97.1 % -98.8%
Return On Assets -383 % -83.6%
Operating Margin -154 % +11.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares 0%
Common Stock, Shares, Outstanding 112M shares 0%
Entity Public Float 7.35M USD +49.7%
Common Stock, Value, Issued 1.12M USD 0%
Weighted Average Number of Shares Outstanding, Basic 112M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 112M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.86M USD -9.41%
Revenue from Contract with Customer, Excluding Assessed Tax 1.86M USD -9.48%
Research and Development Expense 298K USD -0.67%
Operating Income (Loss) -2.87M USD +19.8%
Nonoperating Income (Expense) -232K USD -227%
Net Income (Loss) Attributable to Parent -3.1M USD +15%
Earnings Per Share, Basic -0.03 USD/shares 0%
Earnings Per Share, Diluted -0.03 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 202K USD -63.7%
Accounts Receivable, after Allowance for Credit Loss, Current 180K USD +5.26%
Inventory, Net 75K USD +1.35%
Assets, Current 562K USD -40.1%
Property, Plant and Equipment, Net 12K USD -91.8%
Assets 574K USD -47.1%
Accounts Payable, Current 700K USD +71.1%
Accrued Liabilities, Current 166K USD +22.1%
Liabilities, Current 866K USD +58.9%
Liabilities 4.84M USD +101%
Retained Earnings (Accumulated Deficit) -138M USD -2.3%
Stockholders' Equity Attributable to Parent -4.27M USD -223%
Liabilities and Equity 574K USD -47.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -503K USD -14.3%
Net Cash Provided by (Used in) Financing Activities 500K USD -36.3%
Common Stock, Shares Authorized 200M shares +33.3%
Common Stock, Shares, Issued 112M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3K USD -101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 277K USD -56.2%
Deferred Tax Assets, Valuation Allowance 29.3M USD -3.33%
Deferred Tax Assets, Gross 29.3M USD -3.33%
Depreciation 37K USD
Property, Plant and Equipment, Gross 1.62M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -4.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133M USD +0.12%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 57K USD -28.8%
Interest Expense 111K USD +1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%